Regulation of CD44 alternative splicing by SRm160 and its potential role in tumor cell invasion

Molecular and Cellular Biology

Volumn 26, Issue 1, 2006, Pages 362-370

  Cheng, Chonghui ^a   Sharp, Phillip A ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HERMES ANTIGEN; PROTEIN SRM160; RAS PROTEIN; REGULATOR PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; CELL NUCLEUS ANTIGEN; DNA BINDING PROTEIN; KHDRBS1 PROTEIN, HUMAN; NUCLEAR MATRIX PROTEIN; PHOSPHOPROTEIN; RNA BINDING PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SRRM1 PROTEIN, HUMAN;

ALTERNATIVE RNA SPLICING; ARTICLE; CANCER INVASION; CELL INVASION; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; EXON; GENE ACTIVATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TUMOR CELL; CELL CULTURE; GENETICS; METABOLISM; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ALTERNATIVE SPLICING; ANTIGENS, CD44; ANTIGENS, NUCLEAR; DNA-BINDING PROTEINS; EXONS; HUMANS; NEOPLASM INVASIVENESS; NUCLEAR MATRIX-ASSOCIATED PROTEINS; PHOSPHOPROTEINS; RAS PROTEINS; RNA, SMALL INTERFERING; RNA-BINDING PROTEINS; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 33645220093     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.26.1.362-370.2006     Document Type: Article

References (47)

1. Babic, I., A. Jakymiw, and D. J. Fujita. 2004. The RNA binding protein Sam68 is acetylated in tumor cell lines, and its acetylation correlates with enhanced RNA binding activity. Oncogene 23:3781-3789.
2. Bennett, K. L., D. G. Jackson, J. C. Simon, E. Tanczos, R. Peach, B. Modrell, I. Stamenkovic, G. Plowman, and A. Aruffo. 1995. CD44 isoforms containing exon V3 are responsible for the presentation of heparin-binding growth factor. J. Cell Biol. 128:687-698.
3. Black, D. L. 2003. Mechanisms of alternative pre-messenger RNA splicing. Annu. Rev. Biochem. 72:291-336.
4. Blencowe, B. J., R. Issner, J. A. Nickerson, and P. A. Sharp. 1998. A coactivator of pre-mRNA splicing. Genes Dev. 12:996-1009.
5. Choi, S. H., K. Takahashi, H. Eto, S. S. Yoon, and K. K. Tanabe. 2000. CD44s expression in human colon carcinomas influences growth of liver metastases. Int. J. Cancer 85:523-526.
6. Coulter, L. R., M. A. Landree, and T. A. Cooper. 1997. Identification of a new class of exonic splicing enhancers by in vivo selection. Mol. Cell. Biol. 17:2143-2150.
7. Crozat, A., P. Aman, N. Mandahl. and D. Ron. 1993. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature 363:640-644.
8. Eldridge, A. G., Y. Li, P. A. Sharp, and B. J. Blencowe. 1999. The SRm160/300 splicing coactivator is required for exon-enhancer function. Proc. Natl. Acad. Sci. USA 96:6125-6130.
9. Fairbrother, W. G., R. F. Yeh, P. A. Sharp, and C. B. Burge. 2002. Predictive identification of exonic splicing enhancers in human genes. Science 297:1007-1013.
10. Fumagalli, S., N. F. Totty, J. J. Hsuan, and S. A. Courtneidge. 1994. A target for Src in mitosis. Nature 368:871-874.
11. Gunthert, U., M. Hofmann, W. Rudy, S. Reber, M. Zoller, I. Haussmann, S. Matzku, A. Wenzel, H. Ponta, and P. Herrlich. 1991. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65:13-24.
12. Harn, H. J., L. I. Ho, R. Y. Shyu, J. S. Yuan, F. G. Lin, T. H. Young, C. A. Liu, H. S. Tang, and W. H. Lee. 1996. Soluble CD44 isoforms in serum as potential markers of metastatic gastric carcinoma. J. Clin. Gastroenterol. 22:107-110.
13. Harn, H. J., L. I. Ho, C. P. Yu, M. W. Wang, H. S. Lee, J. J. Lin, W. H. Lee, N. R. Isola, and D. L. Cooper. 1994. The variant mRNA isoform of human metastasis gene (CD44V) detected in the cell lines of human hepatocellular carcinoma. Biochem. Mol. Biol. Int. 32:233-238.
14. Hofmann, M., W. Rudy, U. Gunthert, S. G. Zimmer, V. Zawadzki, M. Zoller, R. B. Lichtner, P. Herrlich, and H. Ponta. 1993. A link between ras and metastatic behavior of tumor cells: ras induces CD44 promoter activity and leads to low-level expression of metastasis-specific variants of CD44 in CREF cells. Cancer Res. 53:1516-1521.
15. Ichikawa, H., K. Shimizu, Y. Hayashi, and M. Ohki. 1994. An RNA-binding protein gene, TLS/FUS, is fused to ERG in human myeloid leukemia with t(16;21) chromosomal translocation. Cancer Res. 54:2865-2868.
16. Jothy, S. 2003. CD44 and its partners in metastasis. Clin. Exp. Metastasis 20:195-201.
17. Katagiri, Y. U., J. Sleeman, H. Fujii, P. Herrlich, H. Hotta, K. Tanaka, S. Chikuma, H. Yagita, K. Okumura, M. Murakami, I. Saiki, A. F. Chambers, and T. Uede. 1999. CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Res. 59:219-226.
18. Konig, H., J. Moll, H. Ponta, and P. Herrlich. 1996. Trans-acting factors regulate the expression of CD44 splice variants. EMBO J. 15:4030-4039.
19. Konig, H., H. Ponta, and P. Herrlich. 1998. Coupling of signal transduction to alternative pre-mRNA splicing by a composite splice regulator. EMBO J. 17:2904-2913.
20. Lee, S. C., H. J. Harn, T. S. Lin, K. T. Yeh, Y. C. Liu, C. S. Tsai, and Y. L. Cheng. 2003. Prognostic significance of CD44v5 expression in human thymic epithelial neoplasms. Ann. Thorac. Surg. 76:213-218.
21. Lin, Q., S. J. Taylor, and D. Shalloway. 1997. Specificity and determinants of Sam68 RNA binding. Implications for the biological function of K homology domains. J. Biol. Chem. 272:27274-27280.
22. Martin, T. A., G. Harrison, R. E. Mansel, and W. G. Jiang. 2003. The role of the CD44/ezrin complex in cancer metastasis. Crit. Rev. Oncol. Hematol. 46:165-186.
23. Matter, N., P. Herrlich, and H. Konig. 2002. Signal-dependent regulation of splicing via phosphorylation of Sam68. Nature 420:691-695.
24. McCracken, S., M. Lambermon, and B. J. Blencowe. 2002. SRml60 splicing coactivator promotes transcript 3′-end cleavage. Mol. Cell. Biol. 22:148-160.
25. McCracken, S., D. Longman, I. L. Johnstone, J. F. Caceres, and B. J. Blencowe. 2003. An evolutionarily conserved role for SRm160 in 3′-end formation that functions independently of exon junction complex formation. J. Biol. Chem. 278:44153-44160.
26. McGarvey, T., E. Rosonina, S. McCracken, Q. Li, R. Arnaout, E. Mientjes, J. A. Nickerson, D. Awrey, J. Greenblatt, G. Grosveld, and B. J. Blencowe. 2000. The acute myeloid leukemia-associated protein, DEK, forms a splicing-dependent interaction with exon-product complexes. J. Cell Biol. 150:309-320.
27. McLaren, M., K. Asai, and A. Cochrane. 2004. A novel function for Sam68: enhancement of HIV-1 RNA 3′ end processing. RNA 10:1119-1129.
28. Meissner, M., S. Lopato, J. Gotzmann, G. Sauermann, and A. Barta. 2003. Proto-oncoprotein TLS/FUS is associated to the nuclear matrix and complexed with splicing factors PTB, SRm160, and SR proteins. Exp. Cell Res. 283:184-195.
29. Morrison, H., L. S. Sherman, J. Legg, F. Banine, C. Isacke, C. A. Haipek, D. H. Gutmann, H. Ponta, and P. Herrlich. 2001. The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev. 15:968-980.
30. Mulder, J. W., P. M. Kruyt, M. Sewnath, C. A. Seldenrijk, W. F. Weidema, S. T. Pals, and G. J. Offerhaus. 1995. Difference in expression of CD44 splice variants between proximal and distal adenocarcinoma of the large bowel. Br. J. Surg. 82:1468-1470.
31. Muller, W., A. Schneiders, K. H. Heider, S. Meier, G. Hommel, and H. E. Gabbert. 1997. Expression and prognostic value of the CD44 splicing variants v5 and v6 in gastric cancer. J. Pathol. 183:222-227.
32. Naor, D., S. Nedvetzki, I. Golan, L. Melnik, and Y. Faitelson. 2002. CD44 in cancer. Crit. Rev. Clin. Lab. Sci. 39:527-579.
33. Orian-Rousseau, V., L. Chen, J. P. Sleeman, P. Herrlich, and H. Ponta. 2002. CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev. 16:3074-3086.
34. Pereira, P. A., U. Rubenthiran, M. Kaneko, S. Jothy, and A. J. Smith. 2001. CD44s expression mitigates the phenotype of human colorectal cancer hepatic metastases. Anticancer Res. 21:2713-2717.
35. Ponta, H., L. Sherman, and P. A. Herrlich. 2003. CD44: from adhesion molecules to signalling regulators. Nat. Rev. Mol. Cell Biol. 4:33-45.
36. Sherman, L., J. Sleeman, P. Dall, A. Hekele, J. Moll, H. Ponta, and P. Herrlich. 1996. The CD44 proteins in embryonic development and in cancer. Curr. Top. Microbiol. Immunol. 213:249-269.
37. Sherman, L., D. Wainwright, H. Ponta, and P. Herrlich. 1998. A splice variant of CD44 expressed in the apical ectodermal ridge presents fibroblast growth factors to limb mesenchyme and is required for limb outgrowth. Genes Dev. 12:1058-1071.
38. Sleeman, J. P., K. Kondo, J. Moll, H. Ponta, and P. Herrlich. 1997. Variant exons v6 and v7 together expand the repertoire of glycosaminoglycans bound by CD44. J. Biol. Chem. 272:31837-31844.
39. Sleeman, J. P., U. Rahmsdorf, A. Steffen, H. Ponta, and P. Herrlich. 1998. CD44 variant exon v5 encodes a tyrosine that is sulphated. Eur. J. Biochem. 255:74-80.
40. Tacke, R., M. Tohyama, S. Ogawa, and J. L. Manley. 1998. Human Tra2 proteins are sequence-specific activators of pre-mRNA splicing. Cell 93:139-148.
41. Taylor, S. J., and D. Shalloway. 1994. An RNA-binding protein associated with Src through its SH2 and SH3 domains in mitosis. Nature 368:867-871.
42. Um, S. J., S. Y. Lee, E. J. Kim, J. Myoung, S. E. Namkoong, and J. S. Park. 2002. Down-regulation of human papillomavirus E6/E7 oncogene by arsenic trioxide in cervical carcinoma cells. Cancer Lett. 181:11-22.
43. van der Voort, R., T. E. Taher, V. J. Wielenga, M. Spaargaren, R. Prevo, L. Smit, G. David, G. Hartmann, E. Gherardi, and S. T. Pals. 1999. Heparan sulfate-modified CD44 promotes hepatocyte growth factor/scatter factor-induced signal transduction through the receptor tyrosine kinase c-Met. J. Biol. Chem. 274:6499-6506.
44. von Lindern, M., M. Fornerod, S. van Baal, M. Jaegle, T. de Wit, A. Buijs, and G. Grosveld. 1992. The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can, and the expression of a chimeric, leukemia-specific dek-can mRNA. Mol. Cell. Biol. 12:1687-1697.
45. Weg-Remers, S., H. Ponta, P. Herrlich, and H. Konig. 2001. Regulation of alternative pre-mRNA splicing by the ERK MAP-kinase pathway. EMBO J. 20:4194-4203.
46. Wu, S. T., G. H. Sun, D. S. Hsieh, A. Chen, H. I. Chen, S. Y. Chang, and D. Yu. 2003. Correlation of CD44v5 expression with invasiveness and prognosis in renal cell carcinoma. J. Formos. Med. Assoc. 102:229-233.
47. Zhu, J., J. Shendure, R. D. Mitra, and G. M. Church. 2003. Single molecule profiling of alternative pre-mRNA splicing. Science 301:836-838.